Gelesis is developing a novel hydrogel platform technology to treat overweight and obesity and chronic diseases related to the GI pathway. Gelesis’ proprietary approach is designed to act mechanically in the GI pathway to potentially alter the course of chronic diseases. In April 2019, Gelesis received FDA clearance for its lead product candidate, PLENITY™(Gelesis 100), as an aid for weight management in overweight and obese adults with a Body Mass Index (BMI) of 25-40 kg/m2, when used in conjunction with diet and exercise. Gelesis is preparing to initiate a targeted U.S. launch of PLENITY in the second half of 2019 and anticipates PLENITY will be broadly available by prescription in the U.S. in 2020. Plenity will initially be manufactured for commercial distribution by Gelesis S.r.l. at its clinical manufacturing facility in Calimera Italy. Gelesis also plans a new commercial-scale manufacturing facility in the region to support anticipated future demand for Plenity in the US, EU and other markets. Additionally, Gelesis is developing its second investigational candidate, Gelesis200, a hydrogel optimized for weight loss and glycemic control in patients with type 2 diabetes and prediabetes. Novel hydrogel mechanotherapeutics based on the Gelesis platform technology are also being advanced through a pipeline in other GI inflammatory conditions where gut barrier and gut permeability potentially play a role, such as non-alcoholic steatohepatitis (NASH), inflammatory bowel disease (IBD) and chronic idiopathic constipation (CIC).
The Gelesis executive and advisory team includes some of the world’s leading experts in obesity, materials science, chronic disease research and commercialization.
Gelesis is interested both in investment/financial agreement (venture capital, private equity, business angel) and cooperation agreement (commercial representation,
know how transfer, distribution agreement, sub-contracting agreement).